Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    stampout
Previous Study | Return to List | Next Study

Study of Antibody for Methamphetamine Outpatient Therapy (STAMPOUT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03336866
Recruitment Status : Completed
First Posted : November 8, 2017
Last Update Posted : September 29, 2021
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
InterveXion Therapeutics, LLC

Brief Summary:
This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels. Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.

Condition or disease Intervention/treatment Phase
Methamphetamine-dependence Methamphetamine Abuse Drug: Placebo Drug: IXT-m200 Phase 1 Phase 2

Detailed Description:
IXT-m200 is a monoclonal antibody that binds to methamphetamine in the blood. The main purpose of this study is to look at the effects of IXT-m200 on the pharmacokinetics of methamphetamine and on methamphetamine liking effects. Additionally, the study will determine IXT-m200 pharmacokinetics, safety and tolerability in subjects with methamphetamine use disorder. Qualified subjects will receive a single dose of IXT-m200 followed by up to 4 methamphetamine challenge doses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy
Actual Study Start Date : May 3, 2018
Actual Primary Completion Date : November 23, 2020
Actual Study Completion Date : March 9, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Placebo Comparator: Placebo
Normal saline
Drug: Placebo
Normal saline

Experimental: IXT-m200
Single 6 or 20 mg/kg intravenous dose of IXT-m200
Drug: IXT-m200
IXT-m200 is an anti-methamphetamine monoclonal antibody
Other Name: ch-mAb7F9

Primary Outcome Measures :
  1. Change in plasma methamphetamine (METH) area under the curve or Cmax resulting from METH challenge doses following single IV doses of IXT-m200 [ Time Frame: 29 days ]
    Measured by plasma concentrations of METH over time

Secondary Outcome Measures :
  1. Change in subjective effects of METH challenge doses [ Time Frame: 26 days ]
    Measured by drug effects questionnaire (ie, reduction of 'High' or 'Liking')

  2. Safety and tolerability of IXT-m200 followed by METH challenges [ Time Frame: 126 days ]
    Measured by physical examinations and vital sign, adverse event, ECG, and clinical laboratory testing, and immune response by measurement of anti-IXT-m200 antibody levels

  3. Pharmacokinetics of IXT-m200 following single administration [ Time Frame: 126 days ]
    Measured by serum concentrations of IXT-m200 over time

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject voluntarily agrees to participate in this study and signs an informed consent form.
  • Subject must be able to verbalize understanding of the consent forms, provide written informed consent, and verbalize willingness to complete study procedures.
  • Males or females between 21 to 50 years of age, inclusive. Female subjects should be of non-childbearing potential or, they should be nonpregnant, nonlactating, and agree to use medically acceptable forms of birth control from screening to end-of-study follow-up, or have a partner who has had a vasectomy. Male subjects need to have had a vasectomy or agree to use a condom and spermicide in addition to their female partners using a form of birth control. They should agree not to donate sperm for 90 days post IXT-m200 dose.
  • Body mass index (BMI) between 18.0 and 35.0 kg/m2. Body weight ≥ 50 kg and ≤ 100 kg.
  • Subjects have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase) < 3 times the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 times the upper limit of normal.
  • Subjects meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for METH use disorder and are not seeking treatment at the time of the study.
  • Subjects will be experienced METH users with a history of non-therapeutic METH use for 2 or more years. Subjects must have experience with smoking or IV injection of METH.
  • Current METH use (past 30 days) less than daily, self-reported and documented by calendar-based timeline follow-back.
  • Primary current (past 30 days) route of METH self-administration other than IV (ie, smoking, snorting, or oral).
  • Subjects agree not to take METH from any source outside of the study during their participation in the study. Subjects agree not to take substances that are structurally similar to METH.
  • Subjects must provide a negative urine sample prior to admission to the unit on Day -1 for the study.

Exclusion Criteria:

  • Subjects who have been treated with a monoclonal antibody (mAb) in the past year.
  • Known or suspected allergy sensitivity to IXT-m200 based on known allergies to other mAbs.
  • History of severe allergy (rash, hives, breathing difficulty, etc) to any medications.
  • History of allergic or environmental bronchial asthma.
  • Clinically significant history of or current abnormality or disease of any organ system, including renal, hepatic, GI, cardiovascular, pulmonary (including chronic asthma), endocrine (eg, diabetes), central nervous, or hematologic systems, or recent clinically significant surgery.
  • Current diagnosis or history of major psychiatric illness in the past two years or other current psychiatric condition requiring medication, other than methamphetamine dependence.
  • Considered by the PI to be at imminent risk of suicide or injury to self, others, or property, or the subject has attempted suicide with the past year. Past year history of, or current evidence for, suicidal ideation or those who were actively suicidal based on the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Current dependence on alcohol or heavy use defined as >28 alcoholic drinks per week if male and >21 drinks per week if female in last 30 days.
  • Current dependence on other drugs except amphetamines, or marijuana and nicotine used in moderate amounts.
  • History of seizure, epilepsy, severe head injury with residual neurologic effects, multiple sclerosis, or stroke.
  • Abnormal pre-admission vital signs, physical examination, clinical laboratory, ECG, or any safety variable which is considered clinically significant for this population.
  • History of cardiovascular disease.
  • Treatment with any prescription medications or over the counter nutritional supplements within 14 days prior to the first dose of study medication.
  • Ingestion of any approved prescription anti-obesity drug or taken any over-the-counter medication for weight loss within a period of 90 days prior to the first dose of study medication.
  • Ingestion or use of any investigational medication or device within 30 days prior to the first dose of study medication.
  • Acute illness within 5 days prior to the first dose of study medication, eg, flu syndrome, GI virus, or clinically significant indigestion (eg, reflux).
  • Positive result for hepatitis B surface antigen (HBsAG), hepatitis C (HepC) antibody, hepatitis A immunoglobulin M (IgM), or HIV Viral Serology, or nucleic acid testing (NAT) tests at screening.
  • Positive breath alcohol test or positive urine drug test for illicit substances on Day -1.
  • Subjects with history of donated blood, plasma, or platelets in last 30 days, and who do not agree to refrain from blood, plasma, platelets, egg or sperm donation during the study period.
  • Predominant or only route of METH self-administration is IV.
  • Any subject judged by the PI or Sponsor (or designee) to be inappropriate for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03336866

Layout table for location information
United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
United States, Utah
PRA Health Sciences
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
InterveXion Therapeutics, LLC
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Lynn Webster, MD PRA Health Sciences
Principal Investigator: Peter Winkle, MD Anaheim Clinical Trials
  Study Documents (Full-Text)

Documents provided by InterveXion Therapeutics, LLC:
Informed Consent Form  [PDF] May 31, 2018

Layout table for additonal information
Responsible Party: InterveXion Therapeutics, LLC Identifier: NCT03336866    
Other Study ID Numbers: M200C-1801
U01DA045366 ( U.S. NIH Grant/Contract )
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: September 29, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Final datasets are expected to contain pharmacokinetic data on IXT-m200 and METH, subjective effects data, immunogenicity totals, and safety data. No individually identifiable private information will be distributed.
Time Frame: These datasets will be available for distribution following submission to the FDA of the Clinical Study Report and publication. They will be available for 2 years after the initial publication.
Access Criteria: These datasets and associated documentation will be made available on CD by the Sponsor to requestors under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology and not distributing to third parties; and (3) a commitment to destroying or returning the data after analyses are completed. Requests should be sent to

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No